Formosa Pharmaceuticals Launches APP13007 in the U.S.
Formosa Pharmaceuticals, Inc. has made a significant advancement in the field of ophthalmic medications by announcing the successful first shipment of APP13007, also known as Clobetasol Propionate Ophthalmic Suspension, 0.05%. This new drug is now ready for commercialization in the United States. Manufactured by Bora Pharmaceuticals Ophthalmic, this shipment marks a crucial milestone in Formosa Pharma's journey.
Innovative Drug Development Fuels Commercialization
Formosa Pharma has utilized its proprietary APNT® nanotechnology platform to create APP13007, which has received FDA approval for ophthalmic use. The introduction of clobetasol propionate—a highly potent corticosteroid—represents a significant breakthrough, especially considering that nearly 7 million ophthalmic surgeries are performed annually in the United States. The ophthalmic steroid market is substantial, valued at approximately USD 1.3 billion, underscoring the importance of this development.
Identifying Market Needs
A recent survey by Eyenovia involving 100 U.S. ophthalmic surgeons highlighted a key insight: both efficacy and cost are critical factors in choosing treatments for postoperative inflammation and pain. APP13007 stands out with its simpler dosing schedule, requiring administration only twice a day, unlike other treatments that may need to be taken four times daily.
Key Milestones on the Path to Global Expansion
In late August, Formosa Pharma obtained a Drug Export License from Taiwan's Food and Drug Administration, enabling its first shipment to the United States. Dr. Erick Co, President & CEO of Formosa Pharma, expressed his excitement about this achievement. He highlighted the importance of this initial shipment to Eyenovia, marking a significant point in the development of APP13007. The company is dedicated to providing valuable therapies to patients undergoing ocular surgery worldwide.
Exploring Opportunities Beyond the U.S.
While the U.S. market presents tremendous potential, Formosa Pharma is also in discussions with partners in various regions to prepare for future regulatory submissions for APP13007. The company aims to make this innovative drug available in diverse international markets, broadening its reach and impact.
About Formosa Pharmaceuticals, Inc.
Formosa Pharmaceuticals, Inc. is a clinical-stage biotechnology company that primarily focuses on ophthalmology and oncology. The company utilizes its proprietary nanoparticle formulation technology, known as APNT®, to improve the dissolution and bioavailability of active pharmaceutical ingredients (APIs) intended for topical, oral, and inhaler applications. Consequently, their formulations demonstrate exceptional uniformity, purity, and stability, facilitating the effective delivery of poorly soluble or highly potent drug agents that typically encounter significant delivery challenges.
Frequently Asked Questions
What is APP13007?
APP13007 is Clobetasol Propionate Ophthalmic Suspension, 0.05%, developed by Formosa Pharmaceuticals to treat postoperative inflammation and pain following ophthalmic surgeries.
How does APP13007 differ from other treatments?
Unlike many treatments that require multiple doses throughout the day, APP13007 only requires administration twice daily, making it a more convenient choice for patients.
What milestone did Formosa Pharmaceuticals recently achieve?
The company successfully completed its first shipment of APP13007 to the U.S. market after receiving a Drug Export License.
Who is the company's U.S. partner for APP13007?
Eyenovia, Inc. is Formosa Pharma's partner in the United States, and they have begun pre-launch activities for the product.
What technology does Formosa Pharmaceuticals utilize?
Formosa Pharmaceuticals employs its proprietary APNT® nanotechnology platform to enhance the formulation and delivery of drugs.
